These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 33292085)

  • 41. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19.
    Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD
    J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Catechin Derivatives as Inhibitor of COVID-19 Main Protease (Mpro): Molecular Docking Studies Unveil an Opportunity Against CORONA.
    Arif MN
    Comb Chem High Throughput Screen; 2022; 25(1):197-203. PubMed ID: 33231155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
    Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
    J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.
    Rakib A; Nain Z; Sami SA; Mahmud S; Islam A; Ahmed S; Siddiqui ABF; Babu SMOF; Hossain P; Shahriar A; Nainu F; Emran TB; Simal-Gandara J
    Brief Bioinform; 2021 Mar; 22(2):1476-1498. PubMed ID: 33623995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
    Poli ANR; Tietjen I; Nandwana NK; Cassel J; Messick TE; Register ET; Keeney F; Rajaiah R; Verma AK; Pandey K; Acharya A; Byrareddy SN; Montaner LJ; Salvino JM
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0056224. PubMed ID: 39225484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.
    Zagórska A; Czopek A; Fryc M; Jończyk J
    Biomolecules; 2024 Jul; 14(7):. PubMed ID: 39062511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
    Ahmad B; Batool M; Ain QU; Kim MS; Choi S
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
    [TBL] [Abstract][Full Text] [Related]  

  • 49.
    Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
    J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.
    Khorsandi Z; Afshinpour M; Molaei F; Askandar RH; Keshavarzipour F; Abbasi M; Sadeghi-Aliabadi H
    J Biomol Struct Dyn; 2022 Oct; 40(17):7940-7948. PubMed ID: 33784944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds.
    Nguyen TH; Thai QM; Pham MQ; Minh PTH; Phung HTT
    Mol Divers; 2024 Apr; 28(2):553-561. PubMed ID: 36823394
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from
    Al-Karmalawy AA; Alnajjar R; Elmaaty AA; Binjubair FA; Al-Rashood ST; Mansour BS; Elkamhawy A; Eldehna WM; Mansour KA
    J Biomol Struct Dyn; 2024 Aug; 42(13):6941-6953. PubMed ID: 37505066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
    Baig MH; Sharma T; Ahmad I; Abohashrh M; Alam MM; Dong JJ
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33802860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.
    Varadharajan V; Arumugam GS; Shanmugam S
    J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L.
    Costanzi E; Kuzikov M; Esposito F; Albani S; Demitri N; Giabbai B; Camasta M; Tramontano E; Rossetti G; Zaliani A; Storici P
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigating the Inhibition of Diindolylmethane Derivatives on SARS-CoV-2 Main Protease.
    Li W; Chang X; Zhou H; Yu W; Wang R; Chang J
    J Mol Recognit; 2024 Nov; 37(6):e3101. PubMed ID: 39221493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.
    Singh R; Gautam A; Chandel S; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.